Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Charter Research LLC

Neither a doctor nor a teaching hospital

Research payments

$63,899,190

925 payments

Through program year 2025, Charter Research LLC is reported as receiving $63,899,190 in research payments, across 925 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $20,849,984 437
2024 Research $14,345,705 269
2023 Research $13,850,089 124
2022 Research $10,961,973 57
2021 Research $3,849,640 31
2020 Research $41,800 7

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $55,138,616 178 payments
  2. Janssen Research & Development, LLC $3,027,715 197 payments
  3. Genentech, Inc. $2,597,386 182 payments
  4. AbbVie, Inc. $1,624,691 182 payments
  5. Roche Diagnostics Operations, Inc. $577,746 28 payments
  6. Avid Radiopharmaceuticals, Inc. $340,368 1 payment
  7. GlaxoSmithKline, LLC. $184,999 82 payments
  8. Sage Therapeutics, Inc. $140,235 6 payments
  9. Regeneron Pharmaceuticals, Inc. $103,350 21 payments
  10. Lexicon Pharmaceuticals, Inc. $60,709 16 payments
Studies the money was for Research payments · program years 2020–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $12,645,225 16 payments
  2. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $4,295,263 11 payments
  3. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $4,095,463 6 payments
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $4,047,959 4 payments
  5. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $3,759,393 4 payments
  6. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $3,741,320 7 payments
  7. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $3,044,313 2 payments
  8. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $2,777,074 138 payments
  9. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $2,509,463 7 payments
  10. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $1,511,394 4 payments
What the money was spent on Research payments · program years 2020–2025
  1. Patient care $34,713 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record